We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using … prices and market shares of brand-names and generics. Then, we exploit a detailed panel data set at product level covering …-savings, and that patients' copayments decrease despite the extra surcharges under RP. …

entry by generic producers. Reference pricing shifts demand towards generics but also induces the branded producer to become …

We study the impact of product margins on pharmacies' incentive to promote generics instead of brand-names. First, we … copayments. Second, we exploit a unique product level panel data set, which contains information on sales and prices at both … generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …

We study the impact of product margins on pharmacies' incentive to promote generics instead of brand-names. First, we … copayments. Second, we exploit a unique product level panel data set, which contains information on sales and prices at both … generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …

We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using … prices and market shares of brand-names and generics. Then, we exploit a detailed panel data set at product level covering …-savings, and that patients' copayments decrease despite the extra surcharges under RP. -- pharmaceuticals ; regulation ; generic …

We study the impact of product margins on pharmacies' incentive to promote generics instead of brand-names. First, we … copayments. Second, we exploit a unique product level panel data set, which contains information on sales and prices at both … generics and their market shares. In terms of policy implications, our results suggest that pharmacy incentives are crucial for …

We study the impact of product margins on pharmacies' incentive to promote generics instead of brand-names. First, we … copayments. Second, we exploit a unique product level panel data set, which contains information on sales and prices at both … generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …